Medivir
Medivir receives European patent for fostrox plus lenvatinib in treatment of hepatocellular carcinoma (HCC) and cancer metastases in the liver
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the European patent authority has granted the company's patent application covering claims for the combination of fostroxacitabine bralpamide (fostrox) with lenvatinib (Lenvima) for the treatment of hepatocellular carcinoma and cancer metastases to the liver. The patent provides protection and market exclusivity until April 2041.
- “This patent approval is, together with the fostrox composition of matter patent, part of our strategy to protect clinically relevant combinations with fostrox in liver cancer. In light of our positive, final data from the phase 1b/2a study presented at the EASL Liver Cancer Summit last month, and the ongoing activities to initiate a phase 2b study in 2nd line HCC, it is key to protect the unique fostrox plus lenvatinib combination in HCC”, says Jens Lindberg, CEO, Medivir.
Datum | 2025-03-19, kl 09:15 |
Källa | MFN |
